Recap: Magenta Therapeutics Q4 Earnings
Magenta Therapeutics (NASDAQ:MGTA) reported its Q4 earnings results on Tuesday, March 8, 2022 at 08:00 AM.
Here's what investors need to know about the announcement.
B. Riley Securities Maintains Buy on Magenta Therapeutics, Lowers Price Target to $6
B. Riley Securities analyst Kalpit Patel maintains Magenta Therapeutics (NASDAQ:MGTA) with a Buy and lowers the price target from $13 to $6.
Stocks That Hit 52-Week Lows On Thursday
During Thursday's morning trading, 152 companies set new 52-week lows.
58 Biggest Movers From Yesterday
Gainers
Eargo, Inc. (NASDAQ: EAR) shares climbed 59.7% to close at $7.28 on Thurs
after the company announced the Department of Justice confirmed to it that the previously-announced criminal probe is no long active.
Goldman Sachs Upgrades Magenta Therapeutics to Buy, Raises Price Target to $8
Goldman Sachs analyst Madhu Kumar upgrades Magenta Therapeutics (NASDAQ:MGTA) from Neutral to Buy and raises the price target from $7 to $8.
Magenta Therapeutics’ Shares Gain As FDA Signs Off Blood Cancer Candidate To Enter Human Trial
The FDA has signed off Magenta Therapeutics Inc’s (NASDAQ:MGTA) IND application for MGTA-117. Related Content: Magenta Therapeutics Stock Drops As FDA Issues…
Stocks That Hit 52-Week Lows On Friday
On Friday morning, 155 companies achieved new lows for the year.